Inside Wall Street: Tiny NeoStem Offers a Chinese Health Care Play

Not many investors know much about tiny NeoStem (NBS), which collects and stores adult stem cells for future medical use. Its stock hit a 52-week high of $2.72 last year but has since tumbled to $1.64. But it may soon attract attention that could propel it back to its old high, if not higher. That's because NeoStem has become an unlikely China health care play.